SPY384.24+0.35 0.09%
DIA311.87+0.10 0.03%
IXIC13,530.92+73.67 0.55%

Krystal Biotech Announces Initiation Of Phase 1 Study Evaluating KB301 In Aesthetic Indications

KB103 is designed to deliver a full-length human type III collagen transgene via intradermal injection First in-human study will evaluate the safety and efficacy in acne scars and facial wrinkles   Initial data

Benzinga · 08/25/2020 12:03

KB103 is designed to deliver a full-length human type III collagen transgene via intradermal injection

First in-human study will evaluate the safety and efficacy in acne scars and facial wrinkles
 

Initial data from this study is anticipated in 2021

PITTSBURGH, Aug. 25, 2020 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (NASDAQ:KRYS), today announced the initiation of the PEARL-1 study, a Phase 1 multi-dose, controlled clinical study of KB301 for the treatment of acne scars and facial wrinkles.

The skin is composed of collagen-rich connective tissue composed primarily of types I and III collagen fibrils. Age-related changes in skin are largely due to aberrant collagen homeostasis, caused both by intrinsic (e.g., passage of time, genetics) and extrinsic (e.g., chronic light exposure, pollution) factors, which leads to progressive loss of dermal collagen. KB301 is designed to restore collagen homeostasis locally via directed expression of full-length human type III collagen gene (COL3A1), thereby reconstructing an optimal physiologic environment in the skin to treat wrinkles and other superficial skin defects. KB301 is manufactured in-house at Krystal's fully functional GMP ANCORIS facility, located near corporate headquarters in Pittsburgh.

"I'm excited to be a part of the ground-breaking PEARL-1 study," Dr. Mark Nestor, director of the Center for Clinical and Cosmetic Research and the Center for Cosmetic Enhancement noted. "I believe KB301 holds the potential to provide a truly innovative and differentiated approach to achieve long lasting collagen production in the aesthetics space."

Chairman and CEO Krish Krishnan further added, "The initiation of this trial is an important step forward for Krystal as we look to demonstrate the potential of our platform in broader skin conditions. If ultimately successful, KB301 and any additional aesthetic programs could represent an interesting strategic opportunity through our wholly-owned subsidiary Jeune, Inc."